[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:alveolar-soft-part-sarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":48,"states":49},"Alveolar Soft Part Sarcoma",6,[7,15,21,28,35,42],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05333458","Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial",[11],"Phase 2","RECRUITING","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:27.511229Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04332874","A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg",[11],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.645373Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT03016819","Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)",[25],"Phase 3","2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.260312Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[32],"Phase 1\u002FPhase 2","2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":40,"content_modified":41},"NCT06113809","Palbociclib and Pembrolizumab in Sarcoma",[39],"Phase 1","2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.898243Z",{"nct_id":43,"title":44,"phases":45,"status":12,"updated_at":46,"content_modified":47},"NCT06066138","A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing",[39],"2026-08-26T02:19:27.519777Z","2026-04-29T02:57:57.119238Z",[],[]]